PvP Biologics launches Phase 1 trials for celiac disease candidate Kuma062

PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety, tolerability, and pharmacodynamics of Kuma062, a promising ... Read More